NEW YORK, Dec. 12, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Centene Corp. (NYSE:CNC) securities between April 26, 2016 and September 6, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/centene-corp. There is no cost or obligation to you.
According to the complaint, during the Class Period, Centene made materially false and misleading statements concerning the acquisition of Health Net, Inc. and failed to disclose: (1) that certain Health Net insurance programs were significantly underperforming, which led to the need to increase reserves to offset losses caused by these programs; (2) that Centene overstated the financial prospects of Health Net; and (3) that as a result of the above, the Company’s statements concerning its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Centene you have until January 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/centene-corp.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Apple Turns 50: From Garage Startup to AI Crossroads 



